Testing a new drug combined with chemotherapy for aggressive blood cancer

This trial is testing whether acalabrutinib—a targeted medication that blocks cancer cell growth—works better when added to standard chemotherapy (called CHOP-R) for newly diagnosed Richter's Syndrome. Richter's Syndrome is a rare but serious transformation of chronic lymphocytic leukaemia, another blood cancer. The trial compares standard chemotherapy alone against chemotherapy combined with the medication to see which approach helps patients live longer and healthier.

Richter's Syndrome is highly aggressive and difficult to treat, with limited treatment options. While small studies suggest the medication may help, no one has directly compared it added to standard treatment versus standard treatment alone, so this trial aims to answer that important question.